Trump ETO Regulatory Rollback

The July 2025 Proclamation

On July 17, 2025, President Trump signed a proclamation granting 41 ethylene oxide commercial sterilization facilities a 2-year extension to comply with the EPA's March 2024 NESHAP emission standards. The proclamation invoked Section 112(i)(4) of the Clean Air Act, a rarely used provision that allows the President to exempt individual sources from emission standards upon a finding that compliance would cause an "unreasonable risk to national security" or would be "technologically infeasible."

The Trump administration framed the exemption as necessary to protect the medical device supply chain, arguing that immediate compliance with the 90%+ emission reduction requirements could force some sterilization facilities to shut down temporarily while installing pollution controls. Industry groups including AdvaMed and the Ethylene Oxide Sterilization Association (EOSA) had lobbied extensively for the delay, providing the administration with analyses projecting supply disruptions for surgical devices, catheters, and implants.

Critics — including the American Lung Association, Environmental Defense Fund, and attorneys representing cancer victims — challenged the premise that a 2-year delay was necessary. They pointed out that the EPA had already provided an 18-month compliance timeline in the 2024 rule, that proven pollution control technologies (catalytic oxidizers, enclosed sterilization systems) were commercially available, and that several major facilities had already begun installing controls before the proclamation was issued.

The legal basis for the proclamation is also contested. Section 112(i)(4) has been invoked only a handful of times in the Clean Air Act's history, and never to exempt an entire class of facilities from a finalized health-based emission standard. Environmental law scholars have argued that the provision was intended for individual facility-specific hardship exemptions, not for blanket industry-wide relief. Legal challenges to the proclamation have been filed in the D.C. Circuit Court of Appeals.

Which Facilities Were Exempted

The July 2025 proclamation specifically identified 41 facilities across the United States that received the 2-year compliance extension. The exempt facilities include some of the largest and most controversial EtO operations in the country, as well as smaller regional sterilizers.

Among the most prominent exempted facilities are: Covidien/Medtronic in North Haven, Connecticut — one of the largest medical device sterilizers in New England, operating in a densely populated suburb of New Haven; Professional Contract Sterilization (PCS) in Taunton, Massachusetts — located near residential neighborhoods and schools; Sterigenics locations in Atlanta, Georgia and other states; and Cosmed Group in Erie, Pennsylvania and Franklin, New Jersey.

The exemption list also includes facilities operated by B. Braun, American Contract Systems, E-BEAM Services, and smaller regional contract sterilizers. Notably, the list does not include the former Sterigenics Willowbrook facility (already closed) or facilities that had already achieved compliance with the 2024 standards. The practical effect is that the 41 exempt facilities can continue operating under pre-2024 emission levels for an additional two years, maintaining the elevated cancer risk for surrounding communities.

Community groups in North Haven, CT, Taunton, MA, and other affected areas organized rapid protests following the proclamation, arguing that the exemption effectively tells residents that their health is less important than industry convenience. Several state attorneys general — including those in Connecticut, Massachusetts, and Illinois — issued statements criticizing the exemption and exploring state-level enforcement alternatives.

Impact on Pending Litigation

The Trump regulatory rollback has complex and somewhat paradoxical effects on pending EtO cancer litigation. On one hand, it undermines one category of legal claims; on the other, it strengthens arguments for punitive damages and willful disregard of community health.

The negative impact is primarily on regulatory negligence claims. In toxic tort litigation, plaintiffs frequently argue that a defendant's failure to comply with applicable regulations constitutes negligence per se — an automatic finding of breach of duty. When the government delays or weakens the applicable regulation, this argument becomes more difficult because defendants can argue they were in compliance with the standards that applied at the time.

However, the Trump exemption actually strengthens several other categories of claims. First, it bolsters willful disregard arguments. The industry's successful lobbying for a compliance delay — after the EPA had determined that immediate compliance was necessary to protect public health — demonstrates that these companies prioritized cost savings over community safety. Internal communications between industry groups and the Trump administration, obtainable through discovery, may reveal the extent to which companies understood the health consequences of delayed compliance and chose to seek the exemption anyway.

Second, the exemption strengthens punitive damages claims. Evidence that a defendant actively lobbied the government to delay health-protective regulations is powerful evidence of the kind of "conscious disregard" for public safety that supports punitive damages in most jurisdictions. The $363 million Kamuda verdict in Georgia included substantial punitive damages precisely because the jury found that Sterigenics had prioritized its financial interests over community health.

Third, the fact that 41 facilities sought and received an exemption can be used to establish industry-wide knowledge of the cancer risk. If these companies believed their EtO emissions were safe, they would not have needed an exemption from emission standards designed to reduce cancer risk. The very act of seeking the exemption is an implicit acknowledgment that current emission levels pose a cancer risk that requires regulatory intervention.

State-Level Enforcement

The Trump administration's retreat from federal EtO enforcement has prompted several states to develop or strengthen their own ethylene oxide emission regulations. This emerging patchwork of state-level action provides alternative accountability mechanisms for affected communities, even as federal standards are delayed.

Illinois was the first mover, enacting the Ethylene Oxide Emissions Standards Act in 2019 following the Willowbrook crisis. The Illinois law requires EtO emitters to meet health-based emission standards that are more stringent than the pre-2024 federal NESHAP. The Illinois EPA has enforcement authority independent of the federal government, and the Sterigenics Willowbrook closure was accomplished through state action, not federal enforcement. Illinois's experience demonstrates that state-level regulation can be effective even when federal action lags.

Georgia has also strengthened its EtO oversight following the Sterigenics litigation. The Georgia Environmental Protection Division (EPD) required the Sterigenics Smyrna facility to install additional emission controls and has increased monitoring requirements for EtO sterilizers operating in the state. While Georgia has not enacted a comprehensive EtO statute comparable to Illinois's, the EPD has used its existing authority under the Georgia Air Quality Act to impose facility-specific emission limits.

Connecticut and Massachusetts are actively exploring state-level EtO regulation in direct response to the Trump exemption. Connecticut's Department of Energy and Environmental Protection (DEEP) has stated it is evaluating whether state environmental law provides independent authority to require emission reductions at the Covidien North Haven facility. Massachusetts has initiated a review of PCS Taunton's state-level permits.

New York has also signaled intent to strengthen state EtO oversight. The New York Department of Environmental Conservation (DEC) has authority under the state's Environmental Conservation Law to impose emission standards that exceed federal requirements. Following the Trump exemption, DEC announced it would review all EtO facility permits in the state, with particular attention to the Sterigenics Queensbury operation.

For plaintiffs in pending litigation, state-level enforcement activity provides additional evidence of the seriousness of EtO exposure risks. State regulatory actions, health studies, and enforcement proceedings are admissible evidence that can supplement the EPA's risk data and support causation arguments at trial. The emerging state-level response also demonstrates that the Trump exemption does not reflect a consensus that EtO emissions are safe — it reflects a political choice to delay federal action while states step in to fill the enforcement gap.